@article{9eba44993a284c04b60dd6ab174db85c,
title = "Response to ''To switch or not to switch': the missing piece in the puzzle of biosimilar literature?' by Scherlinger et al",
keywords = "DMARDs (biologic), anti-TNF, disease activity, outcomes research, Etanercept, Humans, Antirheumatic Agents, Registries, Treatment Outcome, Biosimilar Pharmaceuticals",
author = "Bente Glintborg and Loft, {Anne Gitte} and Emina Omerovic and Oliver Hendricks and Asta Linauskas and Jakob Espesen and Kamilla Danebod and Jensen, {Dorte Vendelbo} and Henrik Nordin and Dalgaard, {Emil Barner} and Stavros Chrysidis and Salome Kristensen and Raun, {Johnny Lillelund} and Hanne Lindegaard and Natalia Manilo and Jakobsen, {Susanne H{\o}jmark} and Hansen, {Inger Marie Jensen} and Pedersen, {Dorte Dalsgaard} and S{\o}rensen, {Inge Juul} and Andersen, {Lis Smedegaard} and Jolanta Grydeh{\o}j and Frank Mehnert and Krogh, {Niels Steen} and {Lund Hetland}, Merete",
year = "2020",
month = apr,
doi = "10.1136/annrheumdis-2018-214952",
language = "English",
volume = "79",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "B M J Group",
number = "4",
}